Short Interest Reporting: Time to Reconsider Abeona Therapeutics Incorporated (NASDAQ:ABEO) After More Short Sellers?

November 23, 2016 - By Louis Casey   ·   0 Comments

Short Interest Reporting: Time to Reconsider Abeona Therapeutics Incorporated (NASDAQ:ABEO) After More Short Sellers?

The stock of Abeona Therapeutics Incorporated (NASDAQ:ABEO) registered an increase of 63.34% in short interest. ABEO’s total short interest was 2.93M shares in November as published by FINRA. Its up 63.34% from 1.79 million shares, reported previously. With 1.10 million shares average volume, it will take short sellers 3 days to cover their ABEO’s short positions. The short interest to Abeona Therapeutics Incorporated’s float is 18.66%. The stock decreased 4.14% or $0.3 during the last trading session, hitting $6.95. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 153.65% since April 21, 2016 and is uptrending. It has outperformed by 148.32% the S&P500.

Abeona Therapeutics, Inc. , formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma products for rare diseases. The company has a market cap of $277.72 million. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. It currently has negative earnings. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc (NASDAQ:ABEO) Ratings Coverage

Out of 3 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $17 is the highest target while $6.0 is the lowest. The $15.50 average target is 123.02% above today’s ($6.95) stock price. Abeona Therapeutics has been the topic of 4 analyst reports since December 16, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, April 20 by Rodman & Renshaw. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has “Buy” rating given on Wednesday, December 16 by Maxim Group. Cantor Fitzgerald initiated the stock with “Buy” rating in Thursday, September 8 report. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned “Buy” rating by Maxim Group on Thursday, September 29.

ABEO Company Profile

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease (COPD) using its salt diafiltration (SDF) ethanol-free process. The Company’s product pipeline also consists of MuGard and ProdiGard.

More recent Abeona Therapeutics Inc (NASDAQ:ABEO) news were published by: Fool.com which released: “Why Abeona Therapeutics Inc. Is Surging Today” on October 18, 2016. Also Benzinga.com published the news titled: “263% Upside Seen In Abeona Therapeutics” on September 21, 2016. Seekingalpha.com‘s news article titled: “Abeona Therapeutics: A Promising Gene Therapy Story” with publication date: October 10, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>